Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 15 February 2018

Shire plc : Director/PDMR Shareholding

Shire plc    

Published: 13:00 CET 15-02-2018 /GlobeNewswire /Source: Shire plc / : SHP /ISIN: JE00B2QKY057

Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding
 
February 15, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")
 
Notification of transactions by person discharging managerial responsibilities
 

1.

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA")

a)

Name

Flemming Ornskov, MD, MPH

2.

Reason for the notification

a)

Position / status

Chief Executive Officer - PDMR

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor

a)

Name

Shire plc

b)

LEI

54930005LQRLI2UXRQ59

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Shire plc American Depositary Shares ("ADSs")

 

 

Identification code

ISIN: US82481R1068

b)

Nature of the transaction

Release of ADSs awarded under the Shire Executive Annual Incentive on February 13, 2015. In accordance with the relevant plan rules, upon release the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the ADSs from the award date to the date of release.

(Details of related disposals of ADSs are referenced in section 5. below.)

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$0

2,546

d)

Aggregated information

- Aggregated volume

- Price

N/A (single transaction)

e)

Date of the transaction

February 13, 2018

f)

Place of the transaction

N/A

5.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Shire plc American Depositary Shares ("ADSs")

 

 

Identification code

ISIN: US82481R1068

b)

Nature of the transaction

Automated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

See appendix below

d)

Aggregated information

- Aggregated volume

- Price

Weighted average price

Aggregate volume

$132.0104

 

1,572

 

e)

Date of the transaction

February 13, 2018

f)

Place of the transaction

ARCX / CDRG / CROS / DBAX / EBXL / INET / NITE / NQPX

 

Appendix

 

Place of the transaction

Aggregate volume

Weighted average price

ARCX

369

$132.1072

CDRG

200

$131.9800

CROS

200

$131.9800

DBAX

100

$131.9900

EBXL

100

$131.9850

INET

203

$131.9716

NITE

300

$131.9800

NQPX

100

$131.9900

Total

1,572

$132.0104

 

Oliver Strawbridge

Senior Assistant Company Secretary


 

For further information please contact:

 

Investor Relations

 

 

Christoph Brackmann

christoph.brackmann@shire.com

+41 795 432 359

Robert Coates

rcoates@shire.com

+44 203 549 0874

Sun Kim

sun.kim@shire.com

+1 617 588 8175

Media

 

 

Lisa Adler

lisa.adler@shire.com

+1 617 588 8607

Katie Joyce

kjoyce@shire.com 

+1 781 482 2779

 

 

NOTES TO EDITORS

 

About Shire

 

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

 

We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people's lives with medicines that have a meaningful impact on patients and all who support them on their journey.

 

www.shire.com

 





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Shire plc, 1 Kingdom Street Paddington, London W2 6BD, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.